Europe needs generic medicines faster
"EU governments need to ensure fast generic medicines uptake as market access and low market volume in key EU countries is
still a real problem and is having a major negative impact on patient access to more affordable treatments."
This was the key message delivered by Greg Perry, Director General of the European Generic Medicines Association (EGA), at
the association's annual conference in Barcelona (Spain) during the launch of a new report, How to Increase Patient Access to Generic Medicines in European Healthcare Systems. The report examines certain aspects of the lack of promotion for competition from generic medicines in the European pharmaceutical
Generic medicines have an important role in ensuring sustainable and affordable healthcare, especially during the global financial
crisis, and also add competition to the marketplace. Despite these benefits, however, there are barriers hindering their market
entry, including the failure of governments to create long-term generic medicines policies, continued price linkage (after
generic medicines market entry) to originator reference products and delays to market caused by post-market authorization
procedures for establishing price and reimbursement status.
Because of barriers such as these, Europe is not fully benefiting from the potential savings offered by generic medicines
competition and the report has made a number of "urgent recommendations". It says "it can be argued that sustainable healthcare
systems can only be achieved through the increased use of generic medicines".
The report made a number of recommendations, including implementing long-term generic medicines policies that remove the potential
barriers and promote the sustainability of the sector, and a mechanism for granting automatic pricing and reimbursement status
upon marketing authorization, which should eliminate current time delays.
Europe isn't the only one suffering from a lack of generic medicines; there are also delays to the market-entry of such medicines
in the US. One possible cause could be brand-makers abusing authorized generics. In a recent US case, Heather Bresch, the
Chief Operating Officer of Mylan, one of the world's largest generic manufacturers, was called to testify as part of a hearing
to gather information about the effects of patent settlements. "When it comes to settlements, Congress need look no further
than the use and abuse of authorized generics by brand manufacturers," said Bresch. "The increase in the number of patent
litigation settlements in recent years is directly related to the increased use of authorized generics during the 180day market
European brand-makers have also been investigated regarding the delayed market entry of generic medicines as part of the EU
sector inquiry, which identified unjustifiable and anticompetitive factors being employed against generic medicines. In a
response made in January 2009 to the preliminary findings of the sector inquiry, the EGA did not highlight, in particular,
the use of authorized generics as a significant hurdle to generic medicines, but did mention brand-makers' "tool box" of strategies,
which includes patent thickets, vexatious litigation and evergreening.
At the EGA conference, Perry said that he was hopeful that the inquiry may go some way to improving timely access to generic
medicines in Europe, which will also offer economic savings to EU governments and patients.
Changes to EU DTC rules?
The European Commission has proposed to allow drugmakers to disseminate certain information on prescription medicines directly
to patients. The UK's Medicines and Healthcare products Regulatory Agency is currently seeking opinions on this proposal.
Read more at:
WHO declares flu pandemic
The pandemic alert has risen to phase 6, but this doesn't mean that it's time to panic. "No previous pandemic has been detected
so early or watched so closely, in real-time, right at the very beginning," said the WHO Director General. "The world can
now reap the benefits of investments, over the last 5 years, in pandemic preparedness."
New directive halted
The preparation of a commission directive on GMPs for certain excipients will no longer continue. The decision was made following
a public consultation, which revealed concerns by stakeholders and member states regarding the lack of flexibility in such
Read more at: